BioTime CEO Explains What Could Happen To Stem Cell Research And The Company Under A New Guard In … – Benzinga
Benzinga |
BioTime CEO Explains What Could Happen To Stem Cell Research And The Company Under A New Guard In …
Benzinga BioTime, Inc. (NYSE: BTX) is a clinical-stage biotechnology company working on regenerative medicine and pluripotent stem cell technologies. Dr. Michael D. West, the original founder of Geron Corporation (NASDAQ: GERN) (and often called “the father of … |
